Vivos Therapeutics, Inc.
VVOS
$2.12
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.78M | 3.82M | 3.02M | 3.70M | 3.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.78M | 3.82M | 3.02M | 3.70M | 3.86M |
| Cost of Revenue | 2.85M | 1.71M | 1.51M | 1.60M | 1.53M |
| Gross Profit | 3.94M | 2.11M | 1.51M | 2.10M | 2.33M |
| SG&A Expenses | 8.29M | 6.67M | 5.25M | 4.76M | 4.83M |
| Depreciation & Amortization | 384.00K | 306.00K | 177.00K | 144.00K | 146.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.52M | 8.69M | 6.93M | 6.50M | 6.51M |
| Operating Income | -4.73M | -4.87M | -3.92M | -2.81M | -2.65M |
| Income Before Tax | -5.40M | -5.01M | -3.86M | -2.83M | -2.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.40M | -5.01M | -3.86M | -2.83M | -2.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.40M | -5.01M | -3.86M | -2.83M | -2.62M |
| EBIT | -4.73M | -4.87M | -3.92M | -2.81M | -2.65M |
| EBITDA | -4.35M | -4.56M | -3.74M | -2.66M | -2.50M |
| EPS Basic | -0.49 | -0.55 | -0.45 | -0.39 | -0.40 |
| Normalized Basic EPS | -0.31 | -0.34 | -0.28 | -0.24 | -0.25 |
| EPS Diluted | -0.49 | -0.55 | -0.45 | -0.39 | -0.40 |
| Normalized Diluted EPS | -0.31 | -0.34 | -0.28 | -0.24 | -0.25 |
| Average Basic Shares Outstanding | 10.96M | 9.09M | 8.60M | 7.23M | 6.62M |
| Average Diluted Shares Outstanding | 10.96M | 9.09M | 8.60M | 7.23M | 6.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |